The impact of immune responses on lung cancer and the development of new treatment modalities

Lung Cancer

Volumn 34, Issue SUPPL. 2, 2001, Pages

  Pluygers, Eric ^a,d   Sadowska, Ala ^b   Chyczewski, Lech ^c   Nikliński, Jacek ^c   Niklińska, Wiesława ^c   Chyczewska, Elzbieta ^c  

^a Hospital de Jolimont   (Belgium)

^b WARSAW UNIVERSITY OF LIFE SCIENCES   (Poland)

^c MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^d NONE   (Belgium)

Author keywords

Adoptive immunotherapy; Cellular immunity; Immune deficiency; Immunotherapy; Lung cancer; Lymphocytes; Monoclonal antibodies; NK cells; Peptide vaccines

Indexed keywords

ANTINEOPLASTIC AGENT; BCG VACCINE; CANCER VACCINE; CELL WALL SKELETON; CETUXIMAB; FAS ANTIGEN; LIGAND; MEMBRANE RECEPTOR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 4D5; PICIBANIL; PSEUDOMONAS EXOTOXIN; RITUXIMAB; TRASTUZUMAB; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACTIVE IMMUNIZATION; ADOPTIVE IMMUNOTHERAPY; APOPTOSIS; BACTERIAL INFECTION; CANCER CONTROL; CANCER IMMUNOTHERAPY; CANCER INCIDENCE; CANCER RISK; CARCINOMA CELL; CELLULAR IMMUNITY; CLINICAL TRIAL; CONFERENCE PAPER; CYTOTOXIC T LYMPHOCYTE; DISEASE ASSOCIATION; EFFECTOR CELL; GRAFT REJECTION; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INDUSTRIALIZATION; LUNG CARCINOMA; POPULATION; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR REGRESSION;

EID: 0035186121     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(01)00348-8     Document Type: Conference Paper

References (65)

1. Cancer, a biological approach
2. Somatic mutation and chronic disease
3. Immunosuppression and cancer
4. Malignant tumors in organ transplant recipients
5. Risk of cancer in renal transplant recipients
6. A collaborative UK-Australasian study of cancer in patients treated with immunosuppressive drugs
7. Secondary neoplasms as a consequence of transplantation and cancer therapy
8. 3 in cardiac-transplant recipients
9. Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment
10. Risks for malignancies in patients with chronic thyroiditis: A long-term follow-up study
11. Cancer mortality in women with thyroid disease
12. Kaposi's sarcoma among persons with AIDS: A sexually transmitted infection?
13. Cancer in a group at risk of acquired immunodeficiency syndrome (AIDS) through 1984
14. Impaired immunity in harbour seals (Phoca vitulina) exposed to bioaccumulated environmental contaminants: Review of a long-term feeding study
15. Organochlorine - Associated immunosuppression in prefledgling Caspian Terns and Herring Gulls from the Great Lakes: An ecoepidemiological study
16. Morbidity follow-up study of BASF employees exposed to 2,3,7,8-TCDD after a chemical reactor incident
17. In utero and postnatal exposure to 2,3,7,8-TCDD in Times Beach, Missouri. 1: Immunological effects: Lymphocyte phenotype frequencies
18. Health effects of dioxin exposure: A 20-year mortality study
19. Increased levels of non-MHC-restricted cytotoxic T lymphocytes (CD3+CD56+) and activated lymphocytes (CD3+Dr+) in peripheral blood as biomarkers of exposure to environmental pollutants in humans
20. Assessment of immune effects of environmental pollutions
21. Exposure to pollutants: Genotoxic effects in plants and immunotoxic effects in humans
22. 0 cytokine secretion patterns
23. Natural Killer Cells in tumour biology
24. Effects of stress on the immune system
25. Human lung carcinomas express Fas Ligand
26. The Oncologist's new dilemma: Chemoimmunotherapy vs. immunochemotherapy
27. Active immunotherapy for acute lymphoblastic leukemia
28. Regional immunotherapy with intrapleural BCG for lung cancer
29. Immunotherapy of lung cancer: A randomized clinical trial of OK-432 immunotherapy and a review of the literature on nonspecific immunotherapy
30. Surgical adjuvant intrapleural BCG treatment for stage I non-small cell lung cancer. Preliminary report of the National Cancer Institute Lung Cancer Study Group
31. Intrapleural BCG in operable lung cancer
32. Active specific immunotherapy with an autologous, tumour cell/BCG vaccine in colorectal cancer
33. Adjuvant, specific, active immunotherapy for resectable squamous cell lung carcinoma: 5-Year survival analysis
34. Lung cancer cell immunogenicity and immunotherapy
35. Genes coding for tumor rejection antigens: Perspectives for specific immunotherapy
36. Expression by 104 non-small cell lung carcinomas of defined antigens recognized by T lymphocytes: Perspectives for anti-cancer vaccines
37. Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation
38. Human neoplasms elicit multiple specific immune responses in the autologous host
39. The treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD monoclonal antibody (Rituxan, Rituximab) and CHOP chemotherapy
40. Expression of the neu gene-encoded protein (p185 neu) in human non-small-cell carcinomas of the lung
41. Cytogenetic abnormalities and overexpression of receptors for growth factors in normal bronchial epithelium and tumour samples of lung cancer patients
42. Overexpression of the C-erbB2/neu encoded p185 protein in primary lung cancer
43. Detection of increased amounts of the extracellular domain of the c-erB-2 oncoprotein in serum during pulmonary carcinogenesis in humans
44. Use of biochemical and molecular biomarkers for cancer risk assessment in humans
45. 2 antibody
46. Humanization of an anti-p185HER-2 antibody for human cancer therapy
47. Herceptin: From the Bench to the clinic
48. 2/neu in lung cancer
49. 225
50. 2/neu overexpression
51. In vivo enhancement of tumor radio-response by C225 anti-epidermal growth factor receptor antibody
52. Accumulation of a recombinant immunotoxin in a tumor in vivo: Fewer than 1000 molecules per cell are sufficient for complete responses
53. Idiotypic networks: Applications for cancer therapy
54. Immune response to the carcinoembryonic antigen in patients treated with an anti-idiotype antibody vaccine
55. Natural Killer cell function in human lung is compartmentalized
56. Tumor antigens recognized by T lymphocytes
57. Isolation and in vitro expansion of lymphocytes infiltrating non-small cell lung carcinoma: Functional and molecular characterization for their use in adoptive immunotherapy
58. 2/neu- derived peptides are shared antigens among human non-small-cell lung cancer and ovarian cancer
59. Lymphokine-activated Killer cell phenomenon: Lysis of natural killer-resistant fresh solid cells by interleukin 2-activated autologous human peripheral blood lymphocytes
60. Immunotherapy with the use of tumor-infiltrating lymphocytes and interleukin-2 as adjuvant treatment in stage III non-small-cell lung cancer. A pilot study
61. Expansion of CD3+CD56+ lymphocytes correlates with induction of cytotoxicity by interleukin-2 gene transfer in human breast tumor cultures
62. Changes in Natural Killer cells, the CD 57 CD8 subset, and related cytokines in healthy aging